In vitro modulator responsiveness of 655 CFTR variants found in people with cystic fibrosis
Journal of Cystic Fibrosis · 2024-07 · 23 (4) · 664-675
DOI: 10.1016/j.jcf.2024.02.006 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Cystic Fibrosis, 2024-07. Verfasst von Hermann Bihler und 18 weiteren Autor:innen. Beteiligte Einrichtung: CFFT Lab, Cystic Fibrosis Foundation, Lexington, MA 02421, USA. Hauptthemen laut MEDLINE: Cystic Fibrosis Transmembrane Conductance Regulator, Cystic Fibrosis, Quinolones, Aminophenols. Die Arbeit wurde bisher 97-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Cystic Fibrosis Foundation.
Abstract (Originalsprache)
BACKGROUND: In 2017, the US Food and Drug Administration initiated expansion of drug labels for the treatment of cystic fibrosis (CF) to include CF transmembrane conductance regulator (CFTR) gene variants based on in vitro functional studies. This study aims to identify CFTR variants that result in increased chloride (Cl-) transport function by the CFTR protein after treatment with the CFTR modulator combination elexacaftor/tezacaftor/ivacaftor (ELX/TEZ/IVA). These data may benefit people with CF (pwCF) who are not currently eligible for modulator therapies. METHODS: Plasmid DNA encoding 655 CFTR variants and wild-type (WT) CFTR were transfected into Fisher Rat Thyroid cells that do not natively express CFTR. After 24 h of incubation with control or TEZ and ELX, and acute addition of IVA, CFTR function was assessed using the transepithelial current clamp conductance assay. Each variant's forskolin/cAMP-induced baseline Cl- transport activity, responsiveness to IVA alone, and responsiveness to the TEZ/ELX/IVA combination were measured in three different laboratories. Western blots were conducted to evaluate CFTR protein maturation and complement the functional data. RESULTS AND CONCLUSIONS: 253 variants not currently approved for CFTR modulator therapy showed low baseline activity (
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- CFFT Lab, Cystic Fibrosis Foundation, Lexington, MA 02421, USA.
- University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.
- Rosalind Franklin University Medical School, Chicago, IL 60064, USA.
- University of Washington, Seattle, WA 98195-9300, USA.
- Johns Hopkins University School of Medicine, Baltimore, MD 21205-2196, USA.
- Cystic Fibrosis Foundation, Bethesda, MD 20814, USA.
Förderung
- Cystic Fibrosis Foundation
Zitieren
APA
Bihler, H., Sivachenko, A., Millen, L., Bhatt, P., Patel, A. T., Chin, J., Bailey, V., Musisi, I., LaPan, A., Allaire, N. E., Conte, J., Simon, N. R., Magaret, A. S., Raraigh, K. S., Cutting, G. R., Skach, W. R., Bridges, R. J., Thomas, P. J., & Mense, M. (2024). In vitro modulator responsiveness of 655 CFTR variants found in people with cystic fibrosis. Journal of Cystic Fibrosis, 23(4), 664-675. https://doi.org/10.1016/j.jcf.2024.02.006
Vancouver
Bihler H, Sivachenko A, Millen L, Bhatt P, Patel AT, Chin J, et al. In vitro modulator responsiveness of 655 CFTR variants found in people with cystic fibrosis. Journal of Cystic Fibrosis. 2024;23(4):664-675. doi:10.1016/j.jcf.2024.02.006
BibTeX
@article{Bihler2024,
author = {Bihler, Hermann and Sivachenko, Andrey and Millen, Linda and Bhatt, Priyanka and Patel, Amita Thakerar and Chin, Justin and Bailey, Violaine and Musisi, Isaac and LaPan, André and Allaire, Normand E and Conte, Joshua and Simon, Noah R and Magaret, Amalia S and Raraigh, Karen S and Cutting, Garry R and Skach, William R and Bridges, Robert J and Thomas, Philip J and Mense, Martin},
title = {In vitro modulator responsiveness of 655 CFTR variants found in people with cystic fibrosis},
journal = {Journal of Cystic Fibrosis},
year = {2024},
volume = {23},
number = {4},
pages = {664--675},
doi = {10.1016/j.jcf.2024.02.006}
}
EUVIMED